Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 44.13% on an annualized basis producing an average annual return of 57.47%. Currently, Moderna has a market capitalization of $51.09 billion.
Buying $100 In MRNA: If an ...
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 44.13% on an annualized basis producing an average annual return of 57.47%. Currently, Moderna has a market capitalization of $51.09 billion.
Buying $100 In MRNA: If an ...
Market Wire News is a media platform, the information on this page was provided by Benzinga via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
2024-06-27 04:27:00 ET The S&P 500 is soaring as this bull market roars on, but some stocks, even those that have rebounded in recent times, still are trading at much lower levels than in the past. In fact, two stocks that have dropped in the double digits over the past few years ar...
2024-06-16 09:45:00 ET Moderna (NASDAQ: MRNA) is best known for its work in the coronavirus vaccine market. That's why the company's stock skyrocketed in the earlier days of the pandemic. It's also why its shares have lagged over the past three years -- its COVID-19 vaccine sales dr...
mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age a...